Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 2.5% – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was down 2.5% during mid-day trading on Tuesday . The company traded as low as GBX 390 ($4.82) and last traded at GBX 395 ($4.88). Approximately 2,561 shares were traded during trading, a decline of 77% from the average daily volume of 11,130 shares. The stock had previously closed at GBX 405 ($5.01).

Hemogenyx Pharmaceuticals Trading Up 3.2 %

The firm has a market capitalization of £5.36 billion, a price-to-earnings ratio of -40,000.00 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38. The company has a 50 day moving average price of GBX 146 and a two-hundred day moving average price of GBX 51.93.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.